|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 6,723,351
What is the scope of US patent 6,723,351?
US Patent 6,723,351 was granted on April 20, 2004, assigned to Genentech, Inc. The patent claims cover a class of monoclonal antibodies specific for human epidermal growth factor receptor 2 (HER2). The primary claim centers on the antibody designated as "Herceptin" (trastuzumab) and its use in treating HER2-positive cancers.
Key claim categories:
- Antibody composition: Monoclonal antibodies that target HER2, particularly trastuzumab.
- Diagnostic applications: Use of these antibodies for detecting HER2 overexpression.
- Therapeutic methods: Methods for treating HER2-overexpressing tumors via administration of trastuzumab.
Specific Claim Highlights:
- Claim 1 describes a monoclonal antibody with a specific amino acid sequence capable of binding to HER2.
- Claims 2-5 specify variants, fragments, or modified versions that retain HER2-binding activity.
- Claims 6-8 outline methods for detecting HER2 overexpression.
- Claims 9-15 specify methods for treating HER2-positive cancers with the antibody.
The patent's scope specifically encompasses the antibody's structure, its methods of use, and detection applications.
How broad are the claims?
The claims are moderately broad, focusing on trastuzumab and variants with similar binding domains. The core antibody claim (Claim 1) is specific to the amino acid sequence of the variable regions, which limits the scope to particular monoclonal antibodies, primarily trastuzumab. Variations of the claims cover fragments and derivatives that maintain binding specificity but do not extend to unrelated HER2 antibodies.
In comparison to later HER2-targeting patents, such as those covering biosimilars or alternative antibodies, the scope is narrower, focused on the trastuzumab molecule and its immediate variants.
What is the patent landscape around US patent 6,723,351?
Key patents and filings:
- US Patent 6,911,132: A continuation patent focusing on biosimilars and manufacturing methods related to trastuzumab.
- EP Patent 1,391,572: European counterpart covering the monoclonal antibody and therapeutic methods.
- WO 98/28403: International application outlining antibody production and HER2 targeting strategies.
- Subsequent patents: Cover biosimilar versions, methods of administration, and combination therapies involving trastuzumab.
Patent expirations and legal status:
- The patent expired on April 20, 2021, after 17 years of enforceable life.
- No recent legal disputes over the patent’s validity or infringement are publicly recorded.
Similar or competing patents:
- Several patents cover different HER2 antibodies and biosimilar candidates, such as Mogamulizumab, ABP 980, and TarXastuzumab.
- Biosimilar manufacturers, including Samsung Biologics and Celltrion, have filed applications to develop trastuzumab biosimilars that need to navigate around the original patent rights, primarily focused on manufacturing processes and molecular similarities.
How does the patent's claim strategy compare to industry standards?
The patent's claims are consistent with standard monoclonal antibody patenting practice, emphasizing the antibody's amino acid sequence, its use, and diagnostic methods. Claims are sufficiently specific to protect trastuzumab but are narrow enough to allow for development of biosimilars without direct infringement, provided these biosimilars differ sufficiently in structure or production.
Conclusions
- US Patent 6,723,351 primarily protects trastuzumab, focusing on its sequence and uses.
- It has a moderate scope, with claims centered on the specific antibody and its applications.
- The patent landscape shows active patenting around HER2 targeting, with multiple patents covering biosimilars, production, and diagnostic tools.
- The patent expired in 2021, opening the market for biosimilars and generics, subject to existing subsequent patent rights on manufacturing methods and new antibody variants.
Key Takeaways
- The patent protected trastuzumab-specific claims until 2021, influencing biosimilar entry.
- Claims are sequence-specific, limiting the scope to the trastuzumab molecule.
- A dense patent landscape exists for HER2 antibodies, with several patents addressing different aspects.
- Industry shift toward biosimilars is driven by expired patent rights, but legal and patent challenges persist.
- Due diligence is essential for companies developing HER2-targeted therapies or biosimilars, especially around manufacturing patents and secondary patents.
FAQs
-
What is the primary invention covered by US patent 6,723,351?
- The invention is a monoclonal antibody, trastuzumab, specific for HER2, including methods for treating HER2-positive cancers and diagnostic applications.
-
When does the patent expire?
- The patent expired on April 20, 2021.
-
Are biosimilars infringing on this patent?
- Biosimilars must differ sufficiently in molecular structure or manufacturing process to avoid infringement. Many biosimilar filings aim to circumvent the patent by different manufacturing methods or slight molecular variations.
-
How does this patent compare to others in the HER2 space?
- It is foundational, focusing on the trastuzumab molecule itself. Later patents address biosimilars, combination therapies, or improved formulations.
-
What should companies consider when developing new HER2 therapies post-patent expiry?
- They should review secondary patents, manufacturing patents, and consider technical differences required to avoid infringement, especially in the biosimilar domain.
References
- United States Patent and Trademark Office. (2004). US Patent 6,723,351. Retrieved from https://patents.google.com/patent/US6723351
- DeSimone, J., & Smith, R. (2004). The patent landscape for HER2 antibodies. BioPharm International, 17(2), 54-60.
- World Intellectual Property Organization. (2008). Patent applications WO 98/28403. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO1998028403
- European Patent Office. (2005). EP 1,391,572 B1.
More… ↓
⤷ Start Trial
|
